Disease · MONDO_0016698
ependymoma
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. ependymoma. Diseases, record MONDO_0016698. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0016698
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
Drugs70
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| CARMUSTINE | CHEMBL513 | Small molecule | Approval | DailyMed | 1 | 0 | 0 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 3 | ClinicalTrials.gov | 16 | 16 | 16 | Drugs and targets |
| CYCLOPHOSPHAMIDE | CHEMBL1200796 | Small molecule | Phase 3 | ClinicalTrials.gov | 14 | 14 | 14 | Drugs and targets |
| METHOTREXATE | CHEMBL34259 | Small molecule | Phase 3 | ClinicalTrials.gov | 11 | 11 | 11 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 3 | ClinicalTrials.gov | 10 | 10 | 10 | Drugs and targets |
| CISPLATIN | CHEMBL11359 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| VINCRISTINE | CHEMBL90555 | Small molecule | Phase 3 | ClinicalTrials.gov | 7 | 7 | 7 | Drugs and targets |
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 3 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| THIOTEPA | CHEMBL671 | Small molecule | Phase 3 | ClinicalTrials.gov | 4 | 4 | 4 | Drugs and targets |
| TROFOSFAMIDE | CHEMBL462019 | Small molecule | Phase 2/3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
1 to 10 of 70
See all 70 drugsTargets150
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 4 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 3 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| PDCD1 | Programmed cell death protein 1 | 3 | Programmed cell death protein 1 inhibitor | Phase 2 | https://conductscience.org/library/genes/5133 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 3 | DNA topoisomerase I inhibitor | Phase 2 | https://conductscience.org/library/genes/7150 | Drugs and targets |
| TUBA1A | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/7846 | Drugs and targets |
| TUBA1B | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/10376 | Drugs and targets |
| TUBA1C | Tubulin | 3 | Tubulin inhibitor | Phase 3 | https://conductscience.org/library/genes/84790 | Drugs and targets |
1 to 10 of 150
See all 150 targetsTrials61
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 4 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01096368 | Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Ependymoma | Phase 3 | 479 | 2023-03-02 | Anaplastic Ependymoma, Brain Ependymoma, Cellular Ependymoma, Clear Cell Ependymoma, Ependymoma, Papillary Ependymoma | CARBOPLATIN, CISPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00027846 | Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma | Phase 2 | 378 | 2017-03-01 | Brain Tumor, Central Nervous System Tumor | CARBOPLATIN, CYCLOPHOSPHAMIDE, ETOPOSIDE, FILGRASTIM, VINCRISTINE | Its record names the disease | ClinicalTrials.gov |
| NCT00602667 | Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma | Phase 2 | 293 | 2019-01-30 | Brain and Central Nervous System Tumors | CYCLOPHOSPHAMIDE, METHOTREXATE, TOPOTECAN, VINBLASTINE | Its record names the disease | ClinicalTrials.gov |
| NCT03130959 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies | Phase 2 | 166 | 2021-04-01 | Various Advanced Cancer | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT04447755 | A Study of Lenvatinib (MK-7902) in Pediatric Participants With Relapsed or Refractory Solid Malignancies (MK-7902-013/E7080) | Phase 2 | 127 | 2023-10-04 | Relapsed or Refractory Solid Tumors | LENVATINIB | Its record names the disease | ClinicalTrials.gov |
| NCT00357500 | Etoposide, Cyclophosphamide, Thalidomide, Celecoxib, and Fenofibrate in Relapsed or Progressive Cancer | Phase 2 | 101 | 2014-09-09 | Central Nervous System Tumor, Pediatric, Leukemia, Lymphoma, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific | CELECOXIB, CYCLOPHOSPHAMIDE, ETOPOSIDE, FENOFIBRATE, THALIDOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00381797 | Bevacizumab and Irinotecan in Treating Young Patients With Recurrent, Progressive, or Refractory Glioma, Medulloblastoma, Ependymoma, or Low Grade Glioma | Phase 2 | 97 | 2013-01-15 | Childhood Cerebral Anaplastic Astrocytoma, Childhood Oligodendroglioma, Childhood Spinal Cord Neoplasm, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma | BEVACIZUMAB, IRINOTECAN HYDROCHLORIDE | Its record names the disease | ClinicalTrials.gov |
| NCT00520936 | A Study of Pemetrexed in Children With Recurrent Cancer | Phase 2 | 72 | 2011-02-23 | Osteosarcoma, Medulloblastoma, Sarcoma, Ewing's, Neuroblastoma (Measurable Disease), Neuroblastoma (Metaiodobenzylguanidine, Positive Evaluable), Rhabdomyosarcoma, Ependymoma, Non-brainstem High-grade Glioma | PEMETREXED | Its record names the disease | ClinicalTrials.gov |
| NCT02125786 | A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma | Phase 2 | 68 | 2024-11-12 | Ependymoma | METHIONINE | Its record names the disease | ClinicalTrials.gov |
| NCT00826241 | Dose-Dense Temozolomide + Lapatinib for Recurrent Ependymoma | Phase 2 | 58 | 2019-03-22 | Brain Tumors, Spinal Cord Tumors | LAPATINIB, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 61
See all 61 trialsComparisons in its trials12
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Radiation (Group 2) vs Sub-Total Resection Any Histology or Location (STR) (Group 3): serious adverse events | 38 of 281 | 55 of 64 | 345 | NCT00027846 | Trial comparisons |
| Stratum A: Recurrent High Grade Glioma vs Stratum B: Recurrent Ependymoma: serious adverse events | 14 of 16 | 9 of 13 | 29 | NCT01462695 | Trial comparisons |
| Intermediate-Risk Group vs High-Risk Group: Participants With PK-guided Dosage Adjustment Achieving Target System Exposure of Intravenous Topotecan | 1 of 1 | 20 of 27 | 28 | NCT00602667 | Trial comparisons |
| Intermediate-Risk Group vs High-Risk Group: Participants With Empirical Dosage Achieving Target System Exposure of Intravenous Topotecan | 0 of 1 | 8 of 27 | 28 | NCT00602667 | Trial comparisons |
| Erlotinib vs Etoposide: serious adverse events | 6 of 13 | 5 of 12 | 25 | NCT01032070 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria for Adverse Events (CTCAE v5.0) | 3 of 3 | 1 of 1 | 4 | NCT03727841 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants That Are Progression-free at 6 Months Time Point After Initiation of Treatment | 1 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants That Have Progressive Disease After 6 Months | 1 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants With 12-month Progression-free Survival (PFS12) | 0 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
1/Cohort 1 - Participants With Ependymoma Who Had None, One or Two Prior Chemotherapies vs 2/Cohort 2 - Participants With Ependymoma Who Had More Than Two Prior Chemotherapies: Number of Participants Assessed Using the Response Assessment in Neuro-oncology Criteria (RANO) for Complete Response (CR) + Partial Response (PR) | 0 of 3 | 0 of 1 | 4 | NCT03727841 | Trial comparisons |
1 to 10 of 12
See all 12 comparisons in its trialsPapers from its trials32
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0016698
GET https://conductscience.org/api/diseases/v1/MONDO_0016698/drugs?page=2